We investigate Alzheimer's disease and related dementia (ADRD) prevalence, incidence
rate, and risk factors in individuals racialized as Asian and/or Asian‐American and assess …

Abstract Background The ADSP‐FUS is a National Institute on Aging (NIA) initiative focused
on identifying genetic risk and protective variants for late‐onset Alzheimer Disease (LOAD) …

With the ageing of the global population, China is projected to be impacted significantly by
the rising number of patients with Alzheimer's disease (AD). A cure for AD is not yet …

Background Genetic studies have primarily been conducted in European ancestry
populations, identifying dozens of loci associated with late-onset Alzheimer's disease (AD) …

Importance Underrepresentation of many racial/ethnic groups in Alzheimer disease (AD)
clinical trials limits generalizability of results and hinders opportunities to examine potential …

Introduction Updated estimates of the US Alzheimer's disease (AD) population, including
under‐represented populations, are needed to improve clinical trial diversity. Methods A …

Background: Alzheimer's disease (AD) begins with an asymptomatic “preclinical” phase, in
which abnormal biomarkers indicate risk for developing cognitive impairment. Research is …

The poor generalizability of clinical research data due to the enrollment of highly educated,
non‐Latinx White participants hampers the development of therapies for Alzheimer's …

The risk of Alzheimer disease (AD) increases with age, family history and informative genetic
variants. Sadly, there is still no cure or means of prevention. As in other complex diseases …

Alzheimer's disease (AD) has no cure, but early detection and risk prediction could allow
earlier intervention. Genetic risk factors may differ between ethnic populations. To discover …